Beaumont Asset Management L.L.C. Has $486,000 Stake in Amgen Inc. (NASDAQ:AMGN)

Beaumont Asset Management L.L.C. lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 3.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 1,687 shares of the medical research company’s stock after buying an additional 62 shares during the period. Beaumont Asset Management L.L.C.’s holdings in Amgen were worth $486,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of AMGN. Vanguard Group Inc. increased its position in shares of Amgen by 0.3% during the third quarter. Vanguard Group Inc. now owns 49,035,981 shares of the medical research company’s stock worth $13,178,910,000 after acquiring an additional 165,636 shares in the last quarter. Northern Trust Corp grew its position in Amgen by 3.8% in the third quarter. Northern Trust Corp now owns 6,977,625 shares of the medical research company’s stock valued at $1,875,306,000 after purchasing an additional 255,463 shares in the last quarter. Bank of New York Mellon Corp grew its position in Amgen by 1.1% in the third quarter. Bank of New York Mellon Corp now owns 5,437,182 shares of the medical research company’s stock valued at $1,461,297,000 after purchasing an additional 61,528 shares in the last quarter. Royal Bank of Canada grew its position in Amgen by 11.4% in the third quarter. Royal Bank of Canada now owns 5,079,677 shares of the medical research company’s stock valued at $1,365,213,000 after purchasing an additional 518,689 shares in the last quarter. Finally, Invesco Ltd. grew its position in Amgen by 15.9% in the third quarter. Invesco Ltd. now owns 3,356,359 shares of the medical research company’s stock valued at $902,055,000 after purchasing an additional 459,340 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on AMGN shares. Truist Financial reaffirmed a “buy” rating and issued a $320.00 target price on shares of Amgen in a research report on Friday, April 12th. Oppenheimer reiterated an “outperform” rating and issued a $350.00 price objective on shares of Amgen in a research note on Thursday, February 1st. Leerink Partnrs lowered shares of Amgen from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 7th. TD Cowen cut their target price on shares of Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a research report on Wednesday, April 17th. Finally, StockNews.com downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research report on Thursday, March 28th. Ten analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $296.95.

Amgen Stock Up 0.6 %

Shares of NASDAQ AMGN traded up $1.63 during trading on Tuesday, hitting $273.54. The stock had a trading volume of 2,492,537 shares, compared to its average volume of 2,834,376. Amgen Inc. has a 12 month low of $211.71 and a 12 month high of $329.72. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The company has a market capitalization of $146.72 billion, a PE ratio of 21.77, a PEG ratio of 2.50 and a beta of 0.58. The firm has a fifty day moving average of $276.45 and a two-hundred day moving average of $281.56.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, beating the consensus estimate of $4.66 by $0.05. The company had revenue of $8.20 billion during the quarter, compared to analyst estimates of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The firm’s revenue for the quarter was up 19.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.09 earnings per share. As a group, equities research analysts forecast that Amgen Inc. will post 19.45 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 3.29%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 72.06%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.